Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant

Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory e...

Full description

Saved in:
Bibliographic Details
Published inProtein engineering, design and selection Vol. 23; no. 5; pp. 375 - 384
Main Authors Atwell, Shane, Brouillette, Christie G., Conners, Kris, Emtage, Spencer, Gheyi, Tarun, Guggino, William B., Hendle, Jorg, Hunt, John F., Lewis, Hal A., Lu, Frances, Protasevich, Irina I., Rodgers, Logan A., Romero, Rich, Wasserman, Stephen R., Weber, Patricia C., Wetmore, Diana, Zhang, Feiyu F., Zhao, Xun
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.05.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387–646(Δ405–436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Å resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542–547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
AbstractList Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387–646(Δ405–436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Å resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The ΔF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542–547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-Aa resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The F508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646(Delta405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-A resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The DeltaF508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can be heterologously expressed and purified in a form that remains stable without solubilizing mutations, stabilizing agents or the regulatory extension (RE). This protein, NBD1 387-646({Delta}405-436), crystallizes as a homodimer with a head-to-tail association equivalent to the active conformation observed for NBDs from symmetric ATP transporters. The 1.7-{angstrom} resolution X-ray structure shows how ATP occupies the signature LSGGQ half-site in CFTR NBD1. The {Delta}F508 version of this protein also crystallizes as a homodimer and differs from the wild-type structure only in the vicinity of the disease-causing F508 deletion. A slightly longer construct crystallizes as a monomer. Comparisons of the homodimer structure with this and previously published monomeric structures show that the main effect of ATP binding at the signature site is to order the residues immediately preceding the signature sequence, residues 542-547, in a conformation compatible with nucleotide binding. These residues likely interact with a transmembrane domain intracellular loop in the full-length CFTR channel. The experiments described here show that removing the RI from NBD1 converts it into a well-behaved protein amenable to biophysical studies yielding deeper insights into CFTR function.
Author Gheyi, Tarun
Zhao, Xun
Brouillette, Christie G.
Conners, Kris
Romero, Rich
Emtage, Spencer
Hendle, Jorg
Weber, Patricia C.
Hunt, John F.
Guggino, William B.
Wetmore, Diana
Atwell, Shane
Protasevich, Irina I.
Wasserman, Stephen R.
Rodgers, Logan A.
Lu, Frances
Zhang, Feiyu F.
Lewis, Hal A.
Author_xml – sequence: 1
  givenname: Shane
  surname: Atwell
  fullname: Atwell, Shane
  email: satwell@lilly.com, To whom correspondence should be addressed. satwell@lilly.com.
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 2
  givenname: Christie G.
  surname: Brouillette
  fullname: Brouillette, Christie G.
  organization: Department of Chemistry and
– sequence: 3
  givenname: Kris
  surname: Conners
  fullname: Conners, Kris
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 4
  givenname: Spencer
  surname: Emtage
  fullname: Emtage, Spencer
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 5
  givenname: Tarun
  surname: Gheyi
  fullname: Gheyi, Tarun
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 6
  givenname: William B.
  surname: Guggino
  fullname: Guggino, William B.
  organization: Department of Physiology, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA
– sequence: 7
  givenname: Jorg
  surname: Hendle
  fullname: Hendle, Jorg
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 8
  givenname: John F.
  surname: Hunt
  fullname: Hunt, John F.
  organization: Department of Biological Sciences, Columbia University, New York, NY 10027, USA
– sequence: 9
  givenname: Hal A.
  surname: Lewis
  fullname: Lewis, Hal A.
  organization: Present address: Department of Macromolecular Crystallography, Bristol-Myers Squibb, Princeton, NJ 08543, USA
– sequence: 10
  givenname: Frances
  surname: Lu
  fullname: Lu, Frances
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 11
  givenname: Irina I.
  surname: Protasevich
  fullname: Protasevich, Irina I.
  organization: Center for Biophysical Sciences and Engineering, University of Alabama at Birmingham, Birmingham, AL 35294, USA
– sequence: 12
  givenname: Logan A.
  surname: Rodgers
  fullname: Rodgers, Logan A.
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 13
  givenname: Rich
  surname: Romero
  fullname: Romero, Rich
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 14
  givenname: Stephen R.
  surname: Wasserman
  fullname: Wasserman, Stephen R.
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 15
  givenname: Patricia C.
  surname: Weber
  fullname: Weber, Patricia C.
  organization: Present address: Imiplex, Yardley, PA 19067, USA
– sequence: 16
  givenname: Diana
  surname: Wetmore
  fullname: Wetmore, Diana
  organization: Cystic Fibrosis Foundation Therapeutics, Bethesda, MD 20814, USA
– sequence: 17
  givenname: Feiyu F.
  surname: Zhang
  fullname: Zhang, Feiyu F.
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
– sequence: 18
  givenname: Xun
  surname: Zhao
  fullname: Zhao, Xun
  organization: Eli Lilly & Co., 10300 Campus Point Drive, San Diego, CA 92121, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20150177$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/1002367$$D View this record in Osti.gov
BookMark eNqFkc9rFDEUx4NU7A-9epTgRYROm0wmk52jLLYrVAptBdlLeJu82Y3OJNskA-rBv72zzrrXnvIIn_f98r7fU3Lkg0dC3nJ2wVkjLrcxZHT-cv3nkbHqBTnhquIF46I6OsxlfUxOU_rBWFkrzl-R45JxybhSJ-TvfY6DyUPERENLgfbOux46uhl68HR-9XBHWxdTpn4wHYbsLBYr563za2pDD85TSLu94EOP8ZxuEGyRQ5HBjSqhD9b9-wdv6RbyJqzRO0P7IYPPr8nLFrqEb_bvGfl29flhvihubq-_zD_dFEYKnouyNBYUFxIUa6WQHEWDbLViSpa84UrODMwUw9ZUTSUqsBaxUcClVMAaW4kz8n7SDSk7nYzLaDYmeI8maz4GI2o1Qh8maAz1ccCUde-Swa4Dj2FIWslq512Wz5NCzOpZxXfGFxNpYkgpYqu3ccw3_h5d9a5BvW9QTw2OC-_20sOqR3vA_1c2Ah_3pwzb58WKiXUp468DDfGnHu9VUi--L_VyIa6_1ss7XYsnwO240A
CitedBy_id crossref_primary_10_1002_pro_3086
crossref_primary_10_1021_jp308315w
crossref_primary_10_1002_cmdc_201000488
crossref_primary_10_3390_ijms21072407
crossref_primary_10_1074_jbc_M115_641134
crossref_primary_10_1007_s12033_014_9830_5
crossref_primary_10_1016_j_jmb_2012_03_001
crossref_primary_10_1042_BJ20121240
crossref_primary_10_1016_j_neuropharm_2017_06_030
crossref_primary_10_1021_acs_jcim_5b00312
crossref_primary_10_1371_journal_pone_0085183
crossref_primary_10_1038_s41598_022_06456_5
crossref_primary_10_1002_1873_3468_13921
crossref_primary_10_1007_s10863_011_9372_5
crossref_primary_10_1002_pro_2460
crossref_primary_10_1038_s41598_017_15997_z
crossref_primary_10_1074_jbc_M112_371138
crossref_primary_10_1016_j_tips_2012_11_006
crossref_primary_10_1016_j_jsb_2016_02_004
crossref_primary_10_1002_pro_3636
crossref_primary_10_1016_j_biocel_2014_04_004
crossref_primary_10_1002_pro_2821
crossref_primary_10_1016_j_cell_2011_11_023
crossref_primary_10_1016_j_bbamem_2016_10_009
crossref_primary_10_1085_jgp_201110608
crossref_primary_10_1016_j_jmb_2010_06_019
crossref_primary_10_1124_mol_117_108373
crossref_primary_10_1016_j_ejmech_2014_06_028
crossref_primary_10_1093_protein_gzx054
crossref_primary_10_1371_journal_pone_0178238
crossref_primary_10_1371_journal_pone_0074347
crossref_primary_10_1021_acs_jpcb_8b11970
crossref_primary_10_1038_s41589_021_00844_0
crossref_primary_10_1085_jgp_201711946
crossref_primary_10_1007_s00018_016_2390_z
crossref_primary_10_1038_s41598_018_22959_6
crossref_primary_10_1007_s00018_022_04671_x
crossref_primary_10_1021_acs_jcim_0c01207
crossref_primary_10_1016_j_molmed_2011_10_003
crossref_primary_10_1074_jbc_M112_420489
crossref_primary_10_1007_s00018_014_1747_4
crossref_primary_10_1038_s41467_019_10714_y
crossref_primary_10_3390_biom4020498
crossref_primary_10_1074_jbc_M115_665125
crossref_primary_10_1073_pnas_1315104110
crossref_primary_10_1007_s00360_012_0664_9
crossref_primary_10_1007_s00018_016_2384_x
crossref_primary_10_1038_nsmb_2741
crossref_primary_10_1042_bse0500233
crossref_primary_10_1002_pro_479
crossref_primary_10_1007_s00018_016_2385_9
crossref_primary_10_1016_j_chembiol_2013_06_004
crossref_primary_10_1371_journal_pone_0015458
crossref_primary_10_1517_17460441_2013_788495
crossref_primary_10_1016_j_abb_2024_110050
crossref_primary_10_1016_j_biocel_2014_01_024
crossref_primary_10_1093_nar_gkq831
crossref_primary_10_3390_jor1030019
crossref_primary_10_1007_s00726_013_1613_y
crossref_primary_10_1074_jbc_M110_131623
crossref_primary_10_1016_j_biochi_2015_01_010
crossref_primary_10_1007_s12551_014_0137_3
crossref_primary_10_1016_j_jmb_2014_07_026
crossref_primary_10_1096_fj_201801218RR
crossref_primary_10_1016_j_bbrc_2019_08_121
crossref_primary_10_1016_j_jbc_2022_101615
crossref_primary_10_1515_hsz_2018_0470
crossref_primary_10_1016_j_bbamem_2018_02_006
crossref_primary_10_1016_j_pbiomolbio_2014_08_004
crossref_primary_10_1074_jbc_RA117_000819
crossref_primary_10_1002_pro_480
crossref_primary_10_1002_1873_3468_13997
Cites_doi 10.1074/jbc.C700175200
10.1038/nrm1949
10.1074/jbc.M410968200
10.1007/s00424-006-0126-x
10.1073/pnas.0709388104
10.1042/BJ20061879
10.1016/j.abb.2008.03.033
10.1002/jmr.753
10.1126/science.2475911
10.1002/pro.5560050111
10.1038/nature04712
10.1038/nature05626
10.1006/abbi.1999.1656
10.1172/JCI117311
10.1038/nature05155
10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2
10.1038/nsmb1278
10.1007/s00210-005-0031-4
10.1042/BJ20050897
10.1038/nature03313
10.1085/jgp.116.2.163
10.1107/S090744490603575X
10.1016/j.molcel.2006.07.034
10.1038/sj.emboj.7600657
10.1126/science.1145950
10.1126/science.1168750
10.1016/S1097-2765(02)00576-2
10.1038/nsmb881
10.1085/jgp.200409174
10.1152/physrev.1999.79.1.S23
10.1126/science.1071142
10.1016/j.molcel.2003.08.004
10.1126/science.1133488
10.1006/jsbi.1999.4094
10.1107/S0907444994003112
10.1038/nature06264
10.1002/pmic.200600028
10.1074/jbc.M111713200
10.1038/sj.emboj.7600040
10.1016/B978-012352551-2/50030-5
10.1016/S0969-2126(01)00617-7
10.1074/jbc.M407434200
ContentType Journal Article
Copyright The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2010
Copyright_xml – notice: The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org 2010
CorporateAuthor Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
CorporateAuthor_xml – name: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7QO
7TM
8FD
FR3
P64
OTOTI
DOI 10.1093/protein/gzq004
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Biotechnology Research Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
OSTI.GOV
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitleList
Engineering Research Database

MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1741-0134
EndPage 384
ExternalDocumentID 1002367
10_1093_protein_gzq004
20150177
10.1093/protein/gzq004
ark_67375_HXZ_ZH3GM6ZR_6
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E4
-~X
.2P
.GJ
.I3
.ZR
0R~
123
18M
1TH
29P
2WC
4.4
482
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAIMJ
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAVLN
AAWDT
ABEJV
ABEUO
ABIXL
ABKDP
ABMNT
ABNHQ
ABNKS
ABPTD
ABQLI
ABQTQ
ABWST
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACIWK
ACMRT
ACPRK
ACUFI
ACUTJ
ACUTO
ADBBV
ADEYI
ADEZT
ADFTL
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZTZ
ADZXQ
AEGPL
AEHUL
AEJOX
AEKSI
AELWJ
AEMDU
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFGWE
AFIYH
AFOFC
AFRAH
AGINJ
AGKEF
AGQXC
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKHUL
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ANFBD
APIBT
APWMN
AQDSO
ARIXL
ATGXG
ATTQO
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BQDIO
BSCLL
BSWAC
BTRTY
BVRKM
C1A
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
D~K
EBD
EBS
EE~
EJD
ELUNK
EMOBN
F5P
F9B
FEDTE
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H13
H5~
HAR
HH5
HVGLF
HW0
HZ~
I-F
IH2
IOX
J21
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
M-Z
M49
N9A
NGC
NLBLG
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAWHX
OBC
OBOKY
OBS
OCZFY
ODMLO
OEB
OES
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RNI
ROL
ROX
RUSNO
RW1
RXO
RZO
SV3
TEORI
TJX
TLC
TR2
W8F
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
AASNB
KC5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7QO
7TM
8FD
FR3
P64
AABJS
AABMN
AAESY
AAIYJ
AANRK
AAPBV
ABPTK
ACIMA
ADEIU
ADORX
ADQLU
AELNO
AFXEN
AGVJH
AIKOY
AIMBJ
AKWXX
ASMCH
AWCFO
AXUDD
AYOIW
AZQFJ
BGYMP
BHONS
BYORX
CASEJ
DPORF
DPPUQ
OTOTI
PQEST
UMP
ID FETCH-LOGICAL-c531t-22cda7135a70f5351e39e0bb0752191758ca870efc49434addee97a1557a09d43
ISSN 1741-0126
IngestDate Fri May 19 01:41:18 EDT 2023
Fri Oct 25 04:13:31 EDT 2024
Fri Oct 25 22:21:59 EDT 2024
Thu Sep 26 16:25:44 EDT 2024
Tue Oct 15 23:36:25 EDT 2024
Wed Aug 28 03:20:15 EDT 2024
Wed Oct 30 09:51:41 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords regulatory insert
NBD1
ABC transporter
CFTR
ΔF508
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c531t-22cda7135a70f5351e39e0bb0752191758ca870efc49434addee97a1557a09d43
Notes ArticleID:gzq004
ark:/67375/HXZ-ZH3GM6ZR-6
istex:AE8DEDFBDA2B031DCF89E0EB12D87FC3CCACD75E
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
USDOE
OpenAccessLink https://academic.oup.com/peds/article-pdf/23/5/375/17494208/gzq004.pdf
PMID 20150177
PQID 733868414
PQPubID 23479
PageCount 10
ParticipantIDs osti_scitechconnect_1002367
proquest_miscellaneous_754535122
proquest_miscellaneous_733868414
crossref_primary_10_1093_protein_gzq004
pubmed_primary_20150177
oup_primary_10_1093_protein_gzq004
istex_primary_ark_67375_HXZ_ZH3GM6ZR_6
PublicationCentury 2000
PublicationDate 2010-05-01
PublicationDateYYYYMMDD 2010-05-01
PublicationDate_xml – month: 05
  year: 2010
  text: 2010-05-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: United States
PublicationTitle Protein engineering, design and selection
PublicationTitleAlternate Protein Eng Des Sel
PublicationYear 2010
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Rich ( key 20170523200433_GZQ004C36) 2005; 18
Wang ( key 20170523200433_GZQ004C43) 2007; 282
Hollenstein ( key 20170523200433_GZQ004C17) 2007; 446
Csanady ( key 20170523200433_GZQ004C9) 2005; 125
Dawson ( key 20170523200433_GZQ004C11) 2006; 443
Cheung ( key 20170523200433_GZQ004C8) 2008; 476
Riordan ( key 20170523200433_GZQ004C37) 1989; 245
Oswald ( key 20170523200433_GZQ004C31) 2006; 372
Smith ( key 20170523200433_GZQ004C40) 2002; 10
Procko ( key 20170523200433_GZQ004C34) 2006; 24
Lu ( key 20170523200433_GZQ004C27) 2000; 375
Chen ( key 20170523200433_GZQ004C7) 2003; 12
Aleksandrov ( key 20170523200433_GZQ004C1) 2002; 277
Atwell ( key 20170523200433_GZQ004C3) 2007; 30
Hvorup ( key 20170523200433_GZQ004C18) 2007; 317
Zaitseva ( key 20170523200433_GZQ004C46) 2005; 24
Ramaen ( key 20170523200433_GZQ004C35) 2005; 391
Linton ( key 20170523200433_GZQ004C23) 2007; 453
Ollero ( key 20170523200433_GZQ004C30) 2006; 6
Pinkett ( key 20170523200433_GZQ004C33) 2007; 315
Guggino ( key 20170523200433_GZQ004C14) 2006; 7
Janin ( key 20170523200433_GZQ004C19) 2007; 63
Yike ( key 20170523200433_GZQ004C45) 1996; 5
Chan ( key 20170523200433_GZQ004C6) 2000; 116
Rosenberg ( key 20170523200433_GZQ004C38) 2004; 279
Locher ( key 20170523200433_GZQ004C24) 2002; 296
Lovell ( key 20170523200433_GZQ004C26) 2000; 40
Lewis ( key 20170523200433_GZQ004C22) 2005; 280
Holland ( key 20170523200433_GZQ004C16) 2003
McRee ( key 20170523200433_GZQ004C28) 1999; 125
Sheppard ( key 20170523200433_GZQ004C39) 1999; 79
Vergani ( key 20170523200433_GZQ004C42) 2005; 433
Baker ( key 20170523200433_GZQ004C4) 2007; 14
Gadsby ( key 20170523200433_GZQ004C13) 2006; 440
CCP4. ( key 20170523200433_GZQ004C5) 1994; 50
Ward ( key 20170523200433_GZQ004C44) 2007; 104
Hanrahan ( key 20170523200433_GZQ004C15) 2003
Thibodeau ( key 20170523200433_GZQ004C41) 2005; 12
Cystic Fibrosis Foundation. ( key 20170523200433_GZQ004C10) 2006
DeLano ( key 20170523200433_GZQ004C12) 2002
Logan ( key 20170523200433_GZQ004C25) 1994; 94
Karpowich ( key 20170523200433_GZQ004C20) 2001; 9
Lewis ( key 20170523200433_GZQ004C21) 2004; 23
Oldham ( key 20170523200433_GZQ004C29) 2007; 450
Aller ( key 20170523200433_GZQ004C2) 2009; 323
Pereira ( key 20170523200433_GZQ004C32) 2007; 405
References_xml – volume: 282
  start-page: 33247
  year: 2007
  ident: key 20170523200433_GZQ004C43
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.C700175200
  contributor:
    fullname: Wang
– volume: 7
  start-page: 426
  year: 2006
  ident: key 20170523200433_GZQ004C14
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/nrm1949
  contributor:
    fullname: Guggino
– volume: 280
  start-page: 1346
  year: 2005
  ident: key 20170523200433_GZQ004C22
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M410968200
  contributor:
    fullname: Lewis
– volume: 453
  start-page: 555
  year: 2007
  ident: key 20170523200433_GZQ004C23
  publication-title: Pflugers Arch.
  doi: 10.1007/s00424-006-0126-x
  contributor:
    fullname: Linton
– volume: 104
  start-page: 19005
  year: 2007
  ident: key 20170523200433_GZQ004C44
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0709388104
  contributor:
    fullname: Ward
– volume: 405
  start-page: 181
  year: 2007
  ident: key 20170523200433_GZQ004C32
  publication-title: Biochem. J.
  doi: 10.1042/BJ20061879
  contributor:
    fullname: Pereira
– volume: 476
  start-page: 95
  year: 2008
  ident: key 20170523200433_GZQ004C8
  publication-title: Arch. Biochem. Biophys
  doi: 10.1016/j.abb.2008.03.033
  contributor:
    fullname: Cheung
– volume: 18
  start-page: 431
  year: 2005
  ident: key 20170523200433_GZQ004C36
  publication-title: J. Mol. Recognit.
  doi: 10.1002/jmr.753
  contributor:
    fullname: Rich
– volume: 245
  start-page: 1066
  year: 1989
  ident: key 20170523200433_GZQ004C37
  publication-title: Science
  doi: 10.1126/science.2475911
  contributor:
    fullname: Riordan
– volume: 5
  start-page: 89
  year: 1996
  ident: key 20170523200433_GZQ004C45
  publication-title: Protein Sci.
  doi: 10.1002/pro.5560050111
  contributor:
    fullname: Yike
– volume: 440
  start-page: 477
  year: 2006
  ident: key 20170523200433_GZQ004C13
  publication-title: Nature
  doi: 10.1038/nature04712
  contributor:
    fullname: Gadsby
– volume: 446
  start-page: 213
  year: 2007
  ident: key 20170523200433_GZQ004C17
  publication-title: Nature
  doi: 10.1038/nature05626
  contributor:
    fullname: Hollenstein
– volume: 375
  start-page: 7
  year: 2000
  ident: key 20170523200433_GZQ004C27
  publication-title: Arch. Biochem. Biophys.
  doi: 10.1006/abbi.1999.1656
  contributor:
    fullname: Lu
– volume: 94
  start-page: 228
  year: 1994
  ident: key 20170523200433_GZQ004C25
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI117311
  contributor:
    fullname: Logan
– volume: 443
  start-page: 180
  year: 2006
  ident: key 20170523200433_GZQ004C11
  publication-title: Nature
  doi: 10.1038/nature05155
  contributor:
    fullname: Dawson
– volume: 40
  start-page: 389
  year: 2000
  ident: key 20170523200433_GZQ004C26
  publication-title: Proteins
  doi: 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2
  contributor:
    fullname: Lovell
– volume: 14
  start-page: 738
  year: 2007
  ident: key 20170523200433_GZQ004C4
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb1278
  contributor:
    fullname: Baker
– volume-title: Patient Registry 2006 Annual Report.
  year: 2006
  ident: key 20170523200433_GZQ004C10
  contributor:
    fullname: Cystic Fibrosis Foundation.
– volume: 372
  start-page: 385
  year: 2006
  ident: key 20170523200433_GZQ004C31
  publication-title: Naunyn Schmiedebergs Arch. Pharmacol.
  doi: 10.1007/s00210-005-0031-4
  contributor:
    fullname: Oswald
– volume: 391
  start-page: 481
  year: 2005
  ident: key 20170523200433_GZQ004C35
  publication-title: Biochem. J.
  doi: 10.1042/BJ20050897
  contributor:
    fullname: Ramaen
– volume: 433
  start-page: 876
  year: 2005
  ident: key 20170523200433_GZQ004C42
  publication-title: Nature
  doi: 10.1038/nature03313
  contributor:
    fullname: Vergani
– volume: 116
  start-page: 163
  year: 2000
  ident: key 20170523200433_GZQ004C6
  publication-title: J. Gen. Physiol.
  doi: 10.1085/jgp.116.2.163
  contributor:
    fullname: Chan
– volume: 63
  start-page: 1
  year: 2007
  ident: key 20170523200433_GZQ004C19
  publication-title: Acta Crystallogr. D Biol. Crystallogr.
  doi: 10.1107/S090744490603575X
  contributor:
    fullname: Janin
– volume: 24
  start-page: 51
  year: 2006
  ident: key 20170523200433_GZQ004C34
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2006.07.034
  contributor:
    fullname: Procko
– volume: 24
  start-page: 1901
  year: 2005
  ident: key 20170523200433_GZQ004C46
  publication-title: Embo. J.
  doi: 10.1038/sj.emboj.7600657
  contributor:
    fullname: Zaitseva
– volume: 317
  start-page: 1387
  year: 2007
  ident: key 20170523200433_GZQ004C18
  publication-title: Science
  doi: 10.1126/science.1145950
  contributor:
    fullname: Hvorup
– volume: 323
  start-page: 1718
  year: 2009
  ident: key 20170523200433_GZQ004C2
  publication-title: Science
  doi: 10.1126/science.1168750
  contributor:
    fullname: Aller
– volume: 10
  start-page: 139
  year: 2002
  ident: key 20170523200433_GZQ004C40
  publication-title: Mol. Cell
  doi: 10.1016/S1097-2765(02)00576-2
  contributor:
    fullname: Smith
– volume-title: The PyMOL Molecular Graphics System.
  year: 2002
  ident: key 20170523200433_GZQ004C12
  contributor:
    fullname: DeLano
– volume: 30
  start-page: 2
  year: 2007
  ident: key 20170523200433_GZQ004C3
  publication-title: Pediatr. Pulmonol. Suppl.
  contributor:
    fullname: Atwell
– volume-title: ABC Proteins: From Bacteria to Man
  year: 2003
  ident: key 20170523200433_GZQ004C16
  contributor:
    fullname: Holland
– volume: 12
  start-page: 10
  year: 2005
  ident: key 20170523200433_GZQ004C41
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb881
  contributor:
    fullname: Thibodeau
– volume: 125
  start-page: 43
  year: 2005
  ident: key 20170523200433_GZQ004C9
  publication-title: J. Gen. Physiol.
  doi: 10.1085/jgp.200409174
  contributor:
    fullname: Csanady
– volume: 79
  start-page: S23
  year: 1999
  ident: key 20170523200433_GZQ004C39
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.1999.79.1.S23
  contributor:
    fullname: Sheppard
– volume: 296
  start-page: 1091
  year: 2002
  ident: key 20170523200433_GZQ004C24
  publication-title: Science
  doi: 10.1126/science.1071142
  contributor:
    fullname: Locher
– volume: 12
  start-page: 651
  year: 2003
  ident: key 20170523200433_GZQ004C7
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2003.08.004
  contributor:
    fullname: Chen
– volume: 315
  start-page: 373
  year: 2007
  ident: key 20170523200433_GZQ004C33
  publication-title: Science
  doi: 10.1126/science.1133488
  contributor:
    fullname: Pinkett
– volume: 125
  start-page: 156
  year: 1999
  ident: key 20170523200433_GZQ004C28
  publication-title: J. Struct. Biol.
  doi: 10.1006/jsbi.1999.4094
  contributor:
    fullname: McRee
– volume: 50
  start-page: 760
  year: 1994
  ident: key 20170523200433_GZQ004C5
  publication-title: Acta Crystallogr. D Biol. Crystallogr.
  doi: 10.1107/S0907444994003112
  contributor:
    fullname: CCP4.
– volume: 450
  start-page: 515
  year: 2007
  ident: key 20170523200433_GZQ004C29
  publication-title: Nature
  doi: 10.1038/nature06264
  contributor:
    fullname: Oldham
– volume: 6
  start-page: 4084
  year: 2006
  ident: key 20170523200433_GZQ004C30
  publication-title: Proteomics
  doi: 10.1002/pmic.200600028
  contributor:
    fullname: Ollero
– volume: 277
  start-page: 15419
  year: 2002
  ident: key 20170523200433_GZQ004C1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M111713200
  contributor:
    fullname: Aleksandrov
– volume: 23
  start-page: 282
  year: 2004
  ident: key 20170523200433_GZQ004C21
  publication-title: Embo J.
  doi: 10.1038/sj.emboj.7600040
  contributor:
    fullname: Lewis
– start-page: 589
  volume-title: ABC Proteins: From Bacteria to Man
  year: 2003
  ident: key 20170523200433_GZQ004C15
  doi: 10.1016/B978-012352551-2/50030-5
  contributor:
    fullname: Hanrahan
– volume: 9
  start-page: 571
  year: 2001
  ident: key 20170523200433_GZQ004C20
  publication-title: Structure
  doi: 10.1016/S0969-2126(01)00617-7
  contributor:
    fullname: Karpowich
– volume: 279
  start-page: 39051
  year: 2004
  ident: key 20170523200433_GZQ004C38
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M407434200
  contributor:
    fullname: Rosenberg
SSID ssj0026711
Score 2.289073
Snippet Upon removal of the regulatory insert (RI), the first nucleotide binding domain (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) can...
SourceID osti
proquest
crossref
pubmed
oup
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 375
SubjectTerms ABC transporter
BASIC BIOLOGICAL SCIENCES
Binding Sites - genetics
CFTR
Cloning, Molecular
Crystallization
Cystic Fibrosis Transmembrane Conductance Regulator - chemistry
Cystic Fibrosis Transmembrane Conductance Regulator - isolation & purification
Dimerization
DNA Primers - genetics
FIBROSIS
GENERAL AND MISCELLANEOUS//MATHEMATICS, COMPUTING, AND INFORMATION SCIENCE
Humans
Models, Molecular
MUTANTS
Mutation - genetics
MUTATIONS
NBD1
NUCLEOTIDES
Protein Conformation
Protein Structure, Tertiary - genetics
PROTEINS
regulatory insert
REMOVAL
RESIDUES
RESOLUTION
ΔF508
Title Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant
URI https://api.istex.fr/ark:/67375/HXZ-ZH3GM6ZR-6/fulltext.pdf
https://www.ncbi.nlm.nih.gov/pubmed/20150177
https://search.proquest.com/docview/733868414
https://search.proquest.com/docview/754535122
https://www.osti.gov/biblio/1002367
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZZ-7KXsbFfWbshxtgeUreJJVvxYykrYbAxmhRCXoxsy6sZibvEgdKH_Yf7n3anU2y3KVu3F2OE5cS6T3cn6e47xt4FoUhlZHzPBLnwJLgAXpLDxMsDBQhSGdg8TBT-_CUcnctP02Da6fxqRS2tq-Qwvb4zr-R_pAptIFfMkv0HydYvhQa4B_nCFSQM13vJeGzJX9dLIo7VPeQJmWNyo92ZPzmdnPXyAty73gJZi8uqyAyuhG0eS1bOdbHAMjPQDzMbSHagmzOvKj0MLO1dlPMyK-ZNjCfWLy7h7xQYiYj1h9u-7VekfEAGkobiEPtlNkbEdl_Zojutk__jahOUPb7Q7QP-co05ihXV7iMChALwfFgfmWB8DlV3QzVVrwvmlaZa8eNLVFnL9qYGnce7TQ3Sw-DoQIPvWLLbbW7v0ylvSlZ2IA1amlhQQRZn1AXVoduyF8SldUnjA3ffrn_0qRzyTWruWyazDmSkI3wRuzfE1P8B2_VB7w2tnWioH0Nly0HX31ZziIoj1_-I-t_wkXZxul-Bx1DCSN9Kw9xaDVmvaPKYPXLLGX5M2HzCOmbxlP1scMnLnGvucMktLjnikltc8m1ccsIl1yvsR7g84G1U8hqVBxxAxRtMcsLkM3Z--nFyMvJcnQ8vBQtQeb6fZhpLRWrVzwMRDIyITD9JwJv1cTshGKYazIrJQatIIdEim0hp8ISV7keZFM_ZzqJcmJeM96M8ScPIpFIZqWSgjbQFUuVQZCoNsy77sBlZkJmlc4nvlmGXvbcDXz-ml98xCFIF8Wg6i2doo8LZWRx22R5KJgaPFWmXU8R_WiEXOJIjdtlbENhff4tv5BmDdscjO5hz5XoVKyGG4VAO_vQIrIFgzHy_y14QFOpf83E7c6DUq3t_9R572EzHfbYDcDGvweuukjcWy78BL-TfPg
link.rule.ids 230,315,783,787,888,27938,27939
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structures+of+a+minimal+human+CFTR+first+nucleotide-binding+domain+as+a+monomer%2C+head-to-tail+homodimer%2C+and+pathogenic+mutant&rft.jtitle=Protein+engineering%2C+design+and+selection&rft.au=Atwell%2C+Shane&rft.au=Brouillette%2C+Christie+G.&rft.au=Conners%2C+Kris&rft.au=Emtage%2C+Spencer&rft.date=2010-05-01&rft.issn=1741-0126&rft.eissn=1741-0134&rft.volume=23&rft.issue=5&rft.spage=375&rft.epage=384&rft_id=info:doi/10.1093%2Fprotein%2Fgzq004&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_protein_gzq004
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-0126&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-0126&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-0126&client=summon